Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody | Zendy

Wang Chao | Zendy; Sun Wujin | Zendy; Wright Grace | Zendy; Wang Andrew Z. | Zendy; Gu Zhen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody

Author(s) -

Wang Chao,

Sun Wujin,

Wright Grace,

Wang Andrew Z.,

Gu Zhen

Publication year - 2016

Publication title -

advanced materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.707

H-Index - 527

eISSN - 1521-4095

pISSN - 0935-9648

DOI - 10.1002/adma.201506312

Subject(s) - cpg site , cpg oligodeoxynucleotide , immunotherapy , cancer , immune system , cancer immunotherapy , inflammation , cancer research , antibody , immunology , biology , gene , gene expression , biochemistry , dna methylation , genetics

Inflammation‐triggered combination delivery of anti‐PD‐1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti‐PD1 and CpG ODN by CpG DNA‐based "nano‐cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research